Literature DB >> 1775714

[Study of high-resolution thoracic computerized tomography and bronchoalveolar lavage in 36 patients presenting with systemic disease and a normal thoracic radiography].

E Dansin1, B Wallaert, M Rémy-Jardin, T Perez, P Y Hatron, J Rémy, A B Tonnel.   

Abstract

Systemic diseases such as scleroderma (ScI), rheumatoid polyarthritis (PR), Gougerot-Sjögren Syndrome (GS) have a well known propensity for the lungs. Previous studies have shown evidence of disturbed alveolar cell repair as evidence of a sub-clinical alveolitis. The significance of such cases of latent alveolitis remains to be specified. To determine if latent alveolitis was associated with interstitial chest disease which was undetectable by chest X-ray, 36 consecutive patients had an BAL and a high resolution computered tomographic examination (HRTC) (Scl: n = 21; PR: n = 9; GS: n = 6). The patients had normal respiratory function and chest X-ray was normal. Our results showed 17 out of 36 (47%) with a latent alveolitis (the percentage of lymphocytes and of alveolar polymorpho-nuclear neutrophils was superior or equal to 18 and 4% respectively) (Scl: 12/21; PR: 1/9; GS: 4/6). In the cases of scleroderma a neutrophil alveolitis was predominant (9/12) and was associated in 2 cases with a honeycomb lung and evidence of fibrotic lesions using TDM-HR. Those examinations using HRTC which were normal were equally associated with a latent alveolitis (Scl: 6/12; PR: 1/6; GR: 4/5). These results suggest that the alveolitis can preceed the anatomical damages. These results need to be confirmed in a larger series and the value of early treatment should be evaluated.

Entities:  

Mesh:

Year:  1991        PMID: 1775714

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  1 in total

1.  High resolution computed tomography for the evaluation of lung involvement in 101 patients with scleroderma.

Authors:  K Dévényi; L Czirják
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.